Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajcnut.2023.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.
J Clin Transl Hepatol
January 2025
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with adverse outcomes such as cirrhosis, malignancy, transplantation, and mortality. Lifestyle modifications constitute the most effective and fundamental management approach, but they often pose challenges in sustaining long-term clinical benefits. Hence, there is a critical need to enhance our understanding through pharmacological management, which unfortunately remains limited.
View Article and Find Full Text PDFAre glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
CNS Spectr
January 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Incretin-based treatments, such as glucagon-like peptide-1 receptor (GLP-1R) agonists (eg liraglutide and semaglutide), have rapidly transformed obesity treatment. The well-documented weight loss effect from these agents is considered to be primarily a result of their actions on food intake, but frequent anecdotal reports from varied sources have suggested that they might also broadly affect consummatory behavior, including alcohol and drugs of abuse, suggesting a potential modulatory effect on reward behavior. Herein, we critically review the extant literature on the behavioral effects of GLP-1R agonists in humans, including their impact on feeding behavior, alcohol/drug intake, and overall reward response.
View Article and Find Full Text PDFLifestyle and Pharmacologic Approaches to Prevention of MASLD-related HCC.
Clin Gastroenterol Hepatol
January 2025
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Hepatocellular carcinoma (HCC) is a major concern for public health. Fatty liver disease, related to alcohol misuse or metabolic syndrome, has become the leading cause of chronic liver disease and HCC. The strong association between type 2 diabetes mellitus and HCC can be partly attributed to the development of metabolic dysfunction associated steatotic liver disease (MASLD).
View Article and Find Full Text PDFThe Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular-Kidney-Metabolic Diseases.
Nephrol Dial Transplant
January 2025
Department of Nephrology, Hospital Universitario 12 de Octubre.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!